Moderate anemia at diagnosis is an independent prognostic marker of the EUTOS, Sokal, and Hasford scores for survival and treatment response in chronic-phase, chronic myeloid leukemia patients with frontline imatinib

References

• Bjorkholm M, Ohm L, Eloranta S, et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol Offic J Am Soc Clin Oncol 2011;29:2514-20
   PubMed Web of Science ®Google Scholar
• de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol Offic J Am Soc Clin Oncol 2008;26:3358-63
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O’Brien S, Jabbour E, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 2012;119:1981-7
   PubMed Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17
   PubMed Web of Science ®Google Scholar
• Hughes TP, Saglio G, Kantarjian HM, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 2014;123:1353-60
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 2014;123:494-500
   PubMed Web of Science ®Google Scholar
• Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122:872-84
   PubMed Web of Science ®Google Scholar
• Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 1984;63:789-99
   PubMed Web of Science ®Google Scholar
• Sokal JE, Baccarani M, Tura S, et al. Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation. Blood 1985;66:1352-7
   PubMed Web of Science ®Google Scholar
• Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998;90:850-8
   PubMed Web of Science ®Google Scholar
• Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 2011;118:686-92
   PubMed Web of Science ®Google Scholar
• Pfirrmann M, Baccarani M, Saussele S, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia 2016;30:48-56
   PubMed Web of Science ®Google Scholar
• Luatti S, Castagnetti F, Marzocchi G, et al. Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. Blood 2012;120:761-7
   PubMed Web of Science ®Google Scholar
• Iurlo A, Ubertis A, Artuso S, et al. Comorbidities and polypharmacy impact on complete cytogenetic response in chronic myeloid leukaemia elderly patients. Eur J Intern Med 2014;25:63-6
   PubMed Web of Science ®Google Scholar
• Hess CE, Ayers CR, Sandusky WR, et al. Mechanism of dilutional anemia in massive splenomegaly. Blood 1976;47:629-44
   PubMed Web of Science ®Google Scholar
• Faber E, Mužík J, Janoušová E, et al. Significance of anemia in patients with CML at diagnosis and during the treatment with imatinib outside the clinical trials: CAMELIA registry experience [abtract]. Eur Hematol Assoc (EHA) 2015;Abstract E1116
   Google Scholar
• Qin YZ, Jiang Q, Jiang H, et al. Combination of white blood cell count at presentation with molecular response at 3 months better predicts deep molecular responses to Imatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients. Medicine 2016;95:e2486
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H, Ghanem H, et al. The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure. Clin Lymph Myeloma Leuk 2013;13:302-6
   PubMed Web of Science ®Google Scholar
• Jabbour E, le Coutre PD, Cortes J, et al. Prediction of outcomes in patients with Ph + chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia 2013;27:907-13
   PubMed Web of Science ®Google Scholar
• Latagliata R, Volpicelli P, Breccia M, et al. Incidence of persistent/late chronic anemia in newly diagnosed patients with chronic myeloid leukemia responsive to imatinib. Am J Hematol 2015;90:105-8
   PubMed Web of Science ®Google Scholar
• Castagnetti F, Gugliotta G, Baccarani M, et al. Differences among young adults, adults and elderly chronic myeloid leukemia patients. Ann Oncol Offic J Eur Soc Med Oncol ESMO 2015;26:185-92
   PubMed Web of Science ®Google Scholar
• Akaike H. Information theory as an extension of the maximum likelihood principle. In: Petrov BN, Csaki F, editors. Second International Symposium on Information Theory. Budapest: Akademiai Kiado; 1973. p 267-81
   Google Scholar
• Forster MR. Key concepts in model selection: performance and generalizability. J Math Psychol 2000;44:205-31
   PubMed Web of Science ®Google Scholar
• Lin HN, Liu CY, Pai JT, et al. How to predict the outcome in mature T and NK cell lymphoma by currently used prognostic models? Blood Cancer J 2012;2:e93
   PubMed Web of Science ®Google Scholar
• Oyekunle AA, Durosinmi MA, Bolarinwa RA, et al. Chronic myeloid leukemia in Nigerian patients: anemia is an independent predictor of overall survival. Clin Med Insights Blood Dsord 2016;9:9-13
   PubMed Web of Science ®Google Scholar
• Guglielmelli P, Rotunno G, Pacilli A, et al. Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients. Am J Hematol 2016;90:918-22
   Web of Science ®Google Scholar
• Kantarjian HM, Bueso-Ramos CE, Talpaz M, et al. Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy. Cancer 2005;104:777-80
   PubMed Web of Science ®Google Scholar
• Eliacik E, Isik A, Aydin C, et al. Bone marrow fibrosis may be an effective independent predictor of the ‘TKI drug response level’ in chronic myeloid leukemia. Hematology 2015;20:392-6
   PubMed Web of Science ®Google Scholar
• Berger U, Maywald O, Pfirrmann M, et al. Gender aspects in chronic myeloid leukemia: long-term results from randomized studies. Leukemia 2005;19:984-9
   PubMed Web of Science ®Google Scholar
• Yahng SA, Jang EJ, Choi SY, et al. Prognostic discrimination for early chronic phase chronic myeloid leukemia in imatinib era: comparison of Sokal, Euro, and EUTOS scores in Korean population. Int J Hematol 2014;100:132-40
   PubMed Web of Science ®Google Scholar
• Iriyama N, Hatta Y, Kobayashi S, et al. The European Treatment and Outcome Study score is associated with clinical outcomes and treatment response following European LeukemiaNet 2013 recommendations in chronic-phase chronic myeloid leukemia. Int J Hematol 2014;100:379-85
   PubMed Web of Science ®Google Scholar
• Tao Z, Liu B, Zhao Y, et al. EUTOS score predicts survival and cytogenetic response in patients with chronic phase chronic myeloid leukemia treated with first-line imatinib. Leukemia Res 2014;38:1030-5
   PubMed Web of Science ®Google Scholar
• Yamamoto E, Fujisawa S, Hagihara M, et al. European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients. Cancer Sci 2014;105:105-9
   PubMed Web of Science ®Google Scholar
• Pavlik T, Janousova E, Mayer J, et al. Current survival measures reliably reflect modern sequential treatment in CML: correlation with prognostic stratifications. Am J Hematol 2013;88:790-7
   PubMed Web of Science ®Google Scholar
• Tiribelli M, Bonifacio M, Calistri E, et al. EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia. Leukemia Res 2013;37:1457-60
   PubMed Web of Science ®Google Scholar
• Hoffmann VS, Baccarani M, Lindoerfer D, et al. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. Leukemia 2013;27:2016-22
   PubMed Web of Science ®Google Scholar
• Jabbour E, Cortes J, Nazha A, et al. EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. Blood 2012;119:4524-6
   PubMed Web of Science ®Google Scholar
• Au WY, Caguioa PB, Chuah C, et al. Chronic myeloid leukemia in Asia. Int J Hematol 2009;89:14-23
   PubMed Web of Science ®Google Scholar
• Hoffmann V, Baccarani M, Hasford J, et al. The EUTOS CML score aims to support clinical decision-making. Blood 2012;119:2966-7
   PubMed Web of Science ®Google Scholar